Answers are grounded in this paper and cite their sources.
Objectives Mucormycosis is a rapidly spreading fungal infection affecting those with a compromised immune system. Recently, there has been an increase in the incidence of mucormycosis in leukaemia patients, usually during the neutropenic phase after chemotherapy, leading to increased morbidity and mortality. This study examines mucormycosis' epidemiology in leukaemia patients and the associated diagnostic difficulties. Methods A systematic review of available literature was conducted in the following databases: EMBASE, Ovid MEDLINE, and PROQUEST till July 2022. Search terms included forms of leukaemia, immunosuppression/chemotherapy and mucormycosis. The authors also critically appraised all included evidence using the Critical Appraisal Skills Programme (CASP) tool. However, the AXIS and Joanna Briggs Institute (JBI) tools appraised cross-sectional studies and case reports. Zotero was used as the reference management software. Data extraction was done in Microsoft Excel, and the results were presented as a narrative synthesis. Results Nineteen (6.8%) of the 280 studies retrieved were eligible for inclusion in this review. However, two papers were excluded after critical appraisal because of poor quality. Thus, 17 (6.1%) of the 280 studies were used for narrative synthesis. Of these 17 studies, 3 (18%) were cohort studies, 1 (6%) was a case-control study, 5 (29%) were cross- sectional studies, and 8 (47%) were case reports. All the included studies were based on hospital data and were observational studies. Five (29%) of the 17 studies were focused on children. All five studies on children identified the highest incidence of mucormycosis in acute lymphoblastic leukaemia (ALL) patients. The remaining 12 (71%) studies included people of all ages (0–80 years) without particular emphasis on children. The included studies were observed to be published from 1982 until 2022, although this review had no year restrictions. The extent of co-infection of mucormycosis was highest among acute myeloid leukaemia patients. The most common causative genus was identified as Rhizopus, and the species as Rhizopus oryzae. A strong correlation was seen between environmental risk factors and mucormycosis infection. Diagnosis of mucormycosis with in two weeks showed a higher survival rate. Pathogenesis of mucormycosis at the species level was done to understand its specific characteristics affecting the diagnosis and treatment outcome. Conclusion This review conveys the importance of identifying the risk factors through proper evaluation of the environmental factors to have an early diagnosis and the significance of identifying mucormycosis at the species level for an effective treatment.
No takes yet. Share an insight, caveat, or question.
Ikpeme et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: